Opzelura 1.5 % (Ruxolitinib (Ruxolitinib Phosphate) CREAM) 1.5 %

Ruxolitinib, the active ingredient in Opzelura 1.5%, works by inhibiting Janus kinase (JAK) enzymes, specifically JAK1 and JAK2. These enzymes are involved in cytokine signaling pathways that drive inflammation and immune responses. By blocking these pathways, the cream reduces inflammation and immune activity in the skin, thereby alleviating symptoms of atopic dermatitis and vitiligo.

The usual dose of Opzelura 1.5% is applied as a thin layer to the affected areas of the skin twice a day, morning and evening. The duration of treatment is determined by a healthcare provider and is typically used for a few weeks until symptoms improve. The prescriber sets the exact dosage and treatment duration based on the patient's condition and response to the medication.

The safety of Opzelura 1.5% during pregnancy or breastfeeding has not been established. It is important to consult with a healthcare provider before using this medication if you are pregnant, planning to become pregnant, or breastfeeding. The healthcare provider will weigh the potential benefits and risks to determine the appropriate course of treatment.

To order Opzelura 1.5% from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will then provide pricing, availability, shipping details, and the necessary import paperwork.

Opzelura 1.5% is a non-steroidal topical treatment that works by inhibiting the immune response, making it a suitable alternative for patients who do not respond well to other topical treatments or who cannot use steroids. Unlike corticosteroids, it does not carry the risk of skin thinning or other steroid-related side effects. It is the first topical JAK inhibitor approved for the treatment of atopic dermatitis.

Opzelura 1.5% should be stored at room temperature, protected from light and moisture. Keep the medication in its original packaging and out of reach of children. Do not use the cream if it appears discolored or if the consistency has changed. Always follow the storage instructions provided by the manufacturer to ensure the medication remains effective and safe to use.

Opzelura 1.5% is applied as a thin layer to the affected areas of the skin twice a day, morning and evening. Gently rub the cream into the skin, ensuring there is at least 8 hours between applications. Do not use more than 60 grams per week or 100 grams over 2 weeks. Avoid applying the cream to the eyes, mouth, or vagina, and do not cover the treated area with a bandage unless instructed by a healthcare provider.

The most serious risks associated with Opzelura 1.5% include serious infections, such as tuberculosis and shingles, and an increased risk of certain cancers, including lymphoma and skin cancers. Patients should be monitored closely for signs of infection or other concerning symptoms. Regular skin checks are recommended to detect any potential skin cancers early.

Opzelura 1.5% should not be used by individuals with an active, serious infection, including localized infections. It is also not recommended for immunocompromised individuals or those with a known hypersensitivity to ruxolitinib or any of the excipients in the cream. Patients should consult with a healthcare provider to determine if Opzelura 1.5% is appropriate for their specific condition and medical history.